Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Ruth Schwarzer"'
Autor:
Beate Jahn, Martina Lackner, Karl Pugner, Ansgar Hebborn, Petra Schnell-Inderst, Gaby Sroczynski, Andras Fehervary, Imke Schall, Ruth Schwarzer, Bernhard Bornschein, Uwe Siebert, Nikolai Muehlberger, Ursula Rochau, K.R. Saverno, Diana I. Brixner, Magdalena Flatscher-Thoeni
Publikováno v:
Journal of Comparative Effectiveness Research. 4:485-504
Aim: To provide an overview of thresholds for incremental cost–effectiveness ratios (ICERs) representing willingness-to-pay (WTP) across multiple countries and insights into exemptions pertaining to the ICER (e.g., cancer). To compare ICER threshol
Autor:
Nikolai Mühlberger, Stefan Zeuzem, Gaby Sroczynski, Eva Esteban, Annette Conrads-Frank, Davene R. Wright, Uwe Siebert, Ruth Schwarzer
Publikováno v:
Journal of Viral Hepatitis. 17:34-50
We systematically reviewed the evidence for long-term effectiveness and cost-effectiveness of antiviral treatment in patients with chronic hepatitis C. We performed a systematic literature search on the long-term effectiveness and cost-effectiveness
Autor:
Kristin Grabein, Norma Grandi, Jürgen Wasem, Björn Stollenwerk, Volker Klauss, Alexander Göhler, Ruth Schwarzer, Uwe Siebert, Petra Schnell-Inderst
Publikováno v:
Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen. 103:319-329
Zusammenfassung Ziel Ziel dieser Technologiebewertung ist der Vergleich der prognostischen Wertigkeit und der klinischen Effektivitat eines zusatzlichen Screenings von hoch-sensitivem C-reaktivem Protein (hs-CRP) mit einem ausschlieslich auf traditio
Autor:
Ruth Schwarzer, Rebecca A. Miksad, Uwe Siebert, Vera Zietemann, Annette Conrads-Frank, Björn Stollenwerk, Petra Schnell-Inderst, Raffaella Matteucci Gothe
Publikováno v:
International Journal of Technology Assessment in Health Care. 24:371-383
Surrogate endpoints are attractive in clinical trials when the primary endpoint is difficult to measure because of time, costs, the need to test multiple regimens, ethical considerations, or pressure from patient advocacy groups (27;41). In advanced
Autor:
Nikolai Mühlberger, Davene R. Wright, Stefan Zeuzem, Beate Lettmeier, Ruth Schwarzer, Gaby Sroczynski, Uwe Siebert
Publikováno v:
Journal of Hepatology. 49:528-536
Background/Aims Peginterferon plus ribavirin is the state-of-the-art antiviral therapy for prevention of serious complications of hepatitis C. Our aim was to compare market uptake of and access to these drugs across Europe. Methods We collected launc
Autor:
Guenther Gastl, Ursula Rochau, Diana I. Brixner, Gaby Sroczynski, Jerald P. Radich, Ruth Schwarzer, Dominik Wolf, Uwe Siebert, M. Kluibenschaedl, Beate Jahn
Publikováno v:
Applied health economics and health policy. 12(2)
Several tyrosine kinase inhibitors (TKIs) are approved for the treatment of chronic myeloid leukemia (CML). Decision-analytic modeling can help to extrapolate data from short-term clinical trials and also consider quality of life when evaluating diff
Autor:
Katharina Hintringer, Vanadin Seifert-Klauss, Petra Schnell-Inderst, Jürgen Wasem, H Gothe, Theresa Hunger, Ruth Schwarzer, Uwe Siebert
Publikováno v:
International journal of public health. 59(1)
The provision of self-pay medical services is common across health care systems, but understudied. According to the German Medical Association, such services should be medically necessary, recommended or at least justifiable, and requested by the pat
Autor:
N. Mühlberger, U. Siebert, B. Lettmeier, G. Sroczynski, Ruth Schwarzer, A. Conrads-Frank, Stefan Zeuzem
Publikováno v:
Handbook of Disease Burdens and Quality of Life Measures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87d8389c591b62d6a89e1824459cd786
https://doi.org/10.1007/978-0-387-78665-0_76
https://doi.org/10.1007/978-0-387-78665-0_76
Autor:
Ruth, Schwarzer, Petra, Schnell-Inderst, Kristin, Grabein, Alexander, Göhler, Björn, Stollenwerk, Norma, Grandi, Volker, Klauss, Jürgen, Wasem, Uwe, Siebert
Publikováno v:
Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen. 103(6)
To compare the predictive value and the clinical effectiveness of additional high sensitivity C-reactive protein (hs-CRP) screening as opposed to traditional risk factor screening alone as a strategy of primary prevention of coronary artery disease (
Autor:
Ruth Schwarzer, Uwe Siebert
Publikováno v:
International journal of technology assessment in health care. 25(3)
Objectives:The objectives of this study were (i) to develop a systematic framework for describing and comparing different features of health technology assessment (HTA) agencies, (ii) to identify and describe similarities and differences between the